Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (381-390 of 662) with videos related to

Pageof 67
Sort By:
Leukemia & Lymphoma|October 3, 2018
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemiaMargaret Nieborowska-Skorska, Silvia Maifrede, Min Ye, et al.
British Journal of Haematology|October 20, 2012
Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosisEszter Rausz, Agnes Szilágyi, Boguslaw Nedoszytko, et al.
Critical Reviews in Oncology/Hematology|February 27, 2010
Neoplastic stem cells: current concepts and clinical perspectivesAxel Schulenburg, Kira Brämswig, Harald Herrmann, et al.
Molecular Oncology|January 29, 2010
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumabGerald W Prager, Eva-Maria Lackner, Maria-Theresa Krauth, et al.
Haematologica|November 21, 2007
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITKaroline V Gleixner, Matthias Mayerhofer, Karoline Sonneck, et al.
Genes, Chromosomes & Cancer|September 23, 2015
Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndromeTheodora Malli, Veronika Buxhofer-Ausch, Melanie Rammer, et al.
International Journal of Molecular Sciences|January 6, 2021
Clinical Impact of Inherited and Acquired Genetic Variants in MastocytosisBoguslaw Nedoszytko, Michel Arock, Jonathan J Lyons, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
American Journal of Cancer Research|October 18, 2021
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing <i>BCR-ABL1</i> <sup>T315I</sup>-compound mutationsKaroline V Gleixner, Yüksel Filik, Daniela Berger, et al.
European Journal of Immunology|January 10, 2002
Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapyInes Swoboda, Nicole De Weerd, Prem L Bhalla, et al.
Pageof 67

Showing results (381-390 of 662) with videos related to

Sort By:
Pageof 67
Leukemia & Lymphoma|October 3, 2018
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemiaMargaret Nieborowska-Skorska, Silvia Maifrede, Min Ye, et al.
British Journal of Haematology|October 20, 2012
Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosisEszter Rausz, Agnes Szilágyi, Boguslaw Nedoszytko, et al.
Critical Reviews in Oncology/Hematology|February 27, 2010
Neoplastic stem cells: current concepts and clinical perspectivesAxel Schulenburg, Kira Brämswig, Harald Herrmann, et al.
Molecular Oncology|January 29, 2010
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumabGerald W Prager, Eva-Maria Lackner, Maria-Theresa Krauth, et al.
Haematologica|November 21, 2007
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITKaroline V Gleixner, Matthias Mayerhofer, Karoline Sonneck, et al.
Genes, Chromosomes & Cancer|September 23, 2015
Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndromeTheodora Malli, Veronika Buxhofer-Ausch, Melanie Rammer, et al.
International Journal of Molecular Sciences|January 6, 2021
Clinical Impact of Inherited and Acquired Genetic Variants in MastocytosisBoguslaw Nedoszytko, Michel Arock, Jonathan J Lyons, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
American Journal of Cancer Research|October 18, 2021
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing <i>BCR-ABL1</i> <sup>T315I</sup>-compound mutationsKaroline V Gleixner, Yüksel Filik, Daniela Berger, et al.
European Journal of Immunology|January 10, 2002
Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapyInes Swoboda, Nicole De Weerd, Prem L Bhalla, et al.
Pageof 67